Phase II study of taxan for refractory esophageal cancer "KTT01"
Phase 2
- Conditions
- esophageal cancer
- Registration Number
- JPRN-UMIN000010057
- Lead Sponsor
- Aichi Cancer Center Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
Symptomatic brain metastasis Paralytic or mechanical bowel obstruction Confirmed or suspected infection Severe pulmonary disease (interstitial pneumonia, pulmonary fobrosis, severe emphysematous) Severe comorbidity (uncontrolable diabetes, heart failure with NYHA 3 or 4, renal failure, liver failure) Pregnant or possibly pregnant, and nursing women Sever neurologic disease Other conditions not suitable for this study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method overall survival
- Secondary Outcome Measures
Name Time Method response rate, disease control rate, progression free survival, toxicity, QO